Ireland-based Endo International has signed an agreement to acquire Par Pharmaceutical Holdings from TPG for $8.05bn.

Under the deal, Par shareholders will receive $6.50bn in cash and 18 million shares worth $1.55bn.

TPG acquired Par Pharmaceutical through its affiliate under a take-private transaction in 2012.

Endo International president and CEO Rajiv De Silva said: "Our generics business, qualitest, continues to be an extremely attractive and effective growth driver for Endo.

"This transaction with Par builds upon our generics growth, adding a strong portfolio of high barrier-to-entry and attractive gross margin products."

"This transaction with Par builds upon our generics growth, adding a strong portfolio of high barrier-to-entry and attractive gross margin products while also transforming Endo, creating a powerful corporate platform for future growth and strategic M&A."

The acquired business is said to expand Endo’s generics business, creating one of the top five businesses in this segment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Par produces around 100 products in multiple dosage forms and delivery systems, including oral solids, oral suspensions, injectables and high barrier-to-entry products.

The company also offers a product pipeline, including more than 200 abbreviated new drug applications (ANDAs), with 115 filed with the US Food and Drug Administration (FDA) as of 31 December 2014.

Par Pharmaceutical CEO Campanelli said: "We share Endo’s goal of developing and commercialising generic drugs in areas of greatest revenue potential, complex formulations and longer lifecycles."

Subject to regulatory approval in the US and certain other jurisdictions, as well as other customary closing conditions, the deal is expected to complete in the second half of this year.